Recursion Pharmaceuticals’ (RXRX) “Buy” Rating Reaffirmed at Needham & Company LLC

Recursion Pharmaceuticals (NASDAQ:RXRX)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research note issued on Monday, Benzinga reports. They presently have a $8.00 target price on the stock. Needham & Company LLC‘s price objective indicates a potential upside of 118.58% from the company’s previous close.

A number of other equities analysts have also commented on RXRX. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Finally, Morgan Stanley set a $5.90 price target on shares of Recursion Pharmaceuticals in a research report on Friday. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.18.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock traded up $0.05 during trading on Monday, hitting $3.66. 20,782,531 shares of the company’s stock traded hands, compared to its average volume of 19,583,299. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The firm’s fifty day moving average price is $3.64 and its 200 day moving average price is $3.42. Recursion Pharmaceuticals has a twelve month low of $2.77 and a twelve month high of $6.70. The company has a market cap of $1.96 billion, a PE ratio of -3.52 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The business had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. During the same quarter last year, the firm posted ($0.41) earnings per share. Analysts forecast that Recursion Pharmaceuticals will post -0.94 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Robert Hershberg sold 25,000 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total value of $125,000.00. Following the transaction, the director directly owned 162,156 shares in the company, valued at $810,780. The trade was a 13.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total transaction of $242,000.00. Following the completion of the transaction, the director owned 6,108,287 shares in the company, valued at approximately $29,564,109.08. This trade represents a 0.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 157,408 shares of company stock worth $643,576 over the last ninety days. Corporate insiders own 6.65% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MCF Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals during the second quarter worth approximately $27,000. Fund Advisors of America Inc FL acquired a new position in shares of Recursion Pharmaceuticals during the second quarter worth approximately $45,000. Integral Investment Advisors Inc. acquired a new position in shares of Recursion Pharmaceuticals during the first quarter worth approximately $39,000. MQS Management LLC acquired a new position in shares of Recursion Pharmaceuticals during the first quarter worth approximately $41,000. Finally, Sequoia Financial Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 51.5% during the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after purchasing an additional 5,156 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.